Type 2 Diabetes Clinical Trials in Little Rock, AR

About Type 2 Diabetes Clinical Trials in Little Rock

Type 2 diabetes is a chronic metabolic condition affecting over 37 million Americans, characterized by insulin resistance and progressive loss of beta-cell function. While metformin remains the first-line treatment, the treatment landscape has expanded dramatically with GLP-1 receptor agonists (semaglutide, tirzepatide), SGLT2 inhibitors (empagliflozin, dapagliflozin), and dual GIP/GLP-1 agonists showing both glycemic and cardiovascular benefits. Clinical trials are now exploring triple-hormone agonists, oral GLP-1 formulations, islet cell regeneration therapies, and precision medicine approaches that tailor treatment to individual metabolic profiles. Patients with uncontrolled HbA1c on current medications, those with diabetic complications, or newly diagnosed patients may qualify for enrollment.

There are currently 9 type 2 diabetes clinical trials recruiting participants in Little Rock, AR. These studies are seeking a combined 4,354 participants. Research is being sponsored by AstraZeneca, Vertex Pharmaceuticals Incorporated, Medtronic MiniMed, Inc. and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.